拉法生醫股份有限公司 Approved
最後更新時間 2025/07/11 , 05:00 AM
最後更新時間 2025/07/11 , 05:00 AM
負責人
Zhuo,Ming-Wei
統一編號
28089461
成立日期
2006/02/07
資本額
NT$300,000,000
實收資本額
NT$129,756,000
股票代號
6848
電話
02-89121200
地址
15F, No. 15, Ciaohe Rd., Zhonghe Dist., New Taipei City, 235, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Zhuo,Ming-Wei Chairman 13.33%
Zhuo,Ming-Xin Director 0.00%
Wang,Kai-Min Director 0.40%
Bai,Shou-Xiong Independent Director 0.00%
Xu,Rui-Xia Independent Director 0.42%
Wu,Chuan-Hui Independent Director 0.41%
Lin,Jian-Ping Independent Director 0.00%
營業項目
  • Manufacture of Other Medical Instruments and Supplies(332900)
  • Wholesale of Other Machinery and Equipment(464915)
  • 公司歷程
  • Change Company Name to RBC BIOSCIENCE CORPORATION
    2024/07/16
  • Change Company Name to RAFFA BIOMEDICAL CO., LTD. (FORMER NAME: RUIBAO BIOMEDICAL CO., LTD.)
    2022/08/03
  • Change Company Name to RBC BIOSCIENCE CORPORATION
    2021/01/11
  • Change Capital to 300,000,000
    2012/07/26
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2024 2023 2022
    Operating income 111,088 172,467 173,891
    Operating cost 59,439 99,572 100,885
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 51,649 72,895 73,006
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 51,649 72,895 73,006
    Operating expenses 30,706 58,356 65,256
    Other gain (loss), net - - -
    Operating profit (loss) 20,943 14,539 7,750
    Non-operating income and expenses -4,513 -6,666 -2,834
    Net profit (loss) before tax 16,430 7,873 4,916
    Income tax expense (benefits) 3,286 1,443 1,138
    Net profit (loss) of ongoing business for the current period 13,144 6,430 3,778
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period 13,144 6,430 3,778
    Other comprehensive profit (loss), net 0 0 0
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period 13,144 6,430 3,778
    Net profit (loss) attributable to owners of parent company - 6,430 3,778
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company - 6,430 3,778
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 1 0 0
    項目 2024 2023 2022
    Net cash inflow (outflow) from operating activities - 13,208 6,603
    Net cash inflows (outflows) from investing activities - 1,003 12,609
    Net cash inflow (outflow) from financing activities - -24,962 -40,750
    Effect of Exchange Rate Changes on Cash and Cash Equivalents - - -
    Increase (decrease) in cash and cash equivalents in the current period - -10,751 -21,538
    Beginning balance of cash and cash equivalents - 75,928 97,466
    Ending balance of cash and cash equivalents - 65,177 75,928
    項目 2024 2023 2022
    Current asset 164,175 140,213 156,898
    Non-current asset 607,539 613,577 633,648
    Total asset 771,714 753,790 790,546
    Current liability 123,440 99,765 123,735
    Non-current liability 400,130 413,316 417,999
    Total liability 523,570 513,081 541,734
    share capital 129,756 129,756 129,756
    Equity - secruity token - - -
    capital reserve 50,450 50,450 50,450
    retained earning 67,938 60,503 68,606
    Other equity 0 0 0
    Treasury stock - - -
    Total equity attributable to owners of parent company - 240,709 248,812
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 248,144 240,709 248,812
    Share capital awaiting retirement (unit: share) 0 0 0
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 19 18 19
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • LyoCore
  • MagCore
  • 拉法生醫股份有限公司標章(一)
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Others
    2022
  • Payment, etc.
    2021
  • Others
    2021
  • Payment, etc.
    2023
  • Petition for the release of the seized property
    2022
  • Petition for confidentiality preservation order
    2021
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。